Aerie Pharmaceuticals (NASDAQ:AERI) has submitted its marketing application in Europe seeking approval of Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
The product was approved in the U.S. in March under the brand name Rocklatan.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.